胃癌肝转移的综合治疗进展

摘要/Abstract

摘要：

胃癌是临床上最常见的消化系统恶性肿瘤之一,具有异质性强、进展快和预后差等特点。胃癌肝转移是造成晚期胃癌死亡最主要的原因。目前,临床上胃癌的治疗方式主要包括系统治疗(全身化疗、靶向治疗、免疫治疗)、手术切除、介入治疗及放疗等,但治疗效果均欠佳,胃癌肝转移更是缺乏规范化的治疗策略。目前,多学科综合治疗模式在恶性肿瘤诊疗中广泛应用,取得了很好的效果。中国胃肠外科专家组根据胃癌肝转移的临床特点及手术可及性,将其分为3大临床类型,分别为可切除型、潜在可切除型及不可切除型。各种临床类型的患者需多学科综合治疗协作组专家讨论后制定出个体化的治疗方案。

关键词:胃肿瘤,肝转移,临床分型,多学科综合治疗

Abstract:

Gastric cancer is one of the most common malignant tumors of digestive system, which has the characteristics of strong heterogeneity, rapid progress and poor prognosis. Liver metastasis of gastric cancer is the main cause of death of advanced gastric cancer. At present, the clinical treatment of gastric cancer mainly includes systematic treatment (systemic chemotherapy, targeted treatment, immunotherapy), surgical resection, interventional treatment and radiotherapy, but the therapeutic effects are not good, and liver metastasis of gastric cancer is lack of standardized treatment strategy. At present, the multi-disciplinary comprehensive treatment mode has been widely used in the diagnosis and treatment of malignant tumors, and has achieved good results. According to the clinical characteristics and surgical accessibility of liver metastasis of gastric cancer, the Chinese Gastrointestinal Surgery Expert Group divides it into three clinical types: resectable type, potential resectable type and non-resectable type. All kinds of clinical types of patients need multidisciplinary comprehensive treatment cooperation group experts to discuss and formulate individualized treatment plan.

Key words:Stomach neoplasms,Liver metastasis,Clinical classification,Multi-disciplinary comprehensive therapy

宋美娇, 沈庆林, 张锡泉, 姚伟荣. 胃癌肝转移的综合治疗进展[J]. 国际肿瘤学杂志, 2020, 47(9): 565-568.

Song Meijiao, Shen Qinglin, Zhang Xiquan, Yao Weirong. Advance in comprehensive treatment of liver metastasis of gastric cancer[J]. Journal of International Oncology, 2020, 47(9): 565-568.

参考文献27

[1]	Zhang Y, Lin Y, Duan J, et al. A population-based analysis of distant metastasis in stage Ⅳ gastric cancer[J]. Med Sci Monit, 2020,26:e923867. DOI: 10.12659/MSM.923867. doi:10.12659/MSM.923867pmid:32409630
[2]	Tang K, Zhang B, Dong L, et al. Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer[J]. J Int Med Res, 2020,48(7):300060520940509. DOI: 10.1177/0300060520940509. doi:10.1177/0300060520940509pmid:32687001
[3]	廖孝枫, 刘合利, 刘鹏. 可切除的局部进展期胃癌及转移性胃癌治疗现状及进展[J]. 中南大学学报(医学版), 2020,45(4):426-434. DOI: 10.11817/j.issn.1672-7347.2020.190079.
[4]	中国研究型医院学会消化道肿瘤专业委员会, 中国医师协会外科医师分会上消化道外科医师委员会, 中国抗癌协会胃癌专业委员会, 等. 胃癌肝转移诊断与综合治疗中国专家共识(2019版)[J]. 中国实用外科杂志, 2019,39(5):405-411. DOI: 10.19538/j.cjps.issn1005-2208.2019.05.01.
[5]	Cui JK, Liu M, Shang XK. Hepatectomy for liver metastasis of gastric cancer: a meta-analysis[J]. Surg Innov, 2019,26(6):692-697. DOI: 10.1177/1553350619856491. doi:10.1177/1553350619856491pmid:31267829
[6]	Montagnani F, Crivelli F, Aprile G, et al. Long-term survival after liver metastasectomy in gastric cancer: systematic review and meta-analysis of prognostic factors[J]. Cancer Treat Rev, 2018,69:11-20. DOI: 10.1016/j.ctrv.2018.05.010. doi:10.1016/j.ctrv.2018.05.010
[7]	Solaini L, Ministrini S, Bencivenga M, et al. Conversion gastrectomy for stage Ⅳ unresectable gastric cancer: a GIRCG retrospective cohort study[J]. Gastric Cancer, 2019,22(6):1285-1293. DOI: 10.1007/s10120-019-00968-2. doi:10.1007/s10120-019-00968-2pmid:31065878
[8]	Kawahara K, Makino H, Kametaka H, et al. Outcomes of surgical resection for gastric cancer liver metastases: a retrospective analysis[J]. World J Surg Oncol, 2020,18(1):41. DOI: 10.1186/s12957-020-01816-9. doi:10.1186/s12957-020-01816-9pmid:32093729
[9]	Guner A, Yildirim R. Surgical management of metastatic gastric cancer: moving beyond the guidelines[J]. Transl Gastroenterol Hepatol, 2019,4:58. DOI: 10.21037/tgh.2019.08.03. doi:10.21037/tgh
[10]	Coccolini F, Nardi M, Montori G, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials[J]. Int J Surg, 2018,51:120-127. DOI: 10.1016/j.ijsu.2018.01.008. doi:10.1016/j.ijsu.2018.01.008pmid:29413875
[11]	Liu Y, Zhao G, Xu Y, et al. Multicenter phase 2 study of peri-irradiation chemotherapy plus intensity modulated radiation therapy with concurrent weekly docetaxel for inoperable or medically unresectable nonmetastatic gastric cancer[J]. Int J Radiat Oncol Biol Phys, 2017,98(5):1096-1105. DOI: 10.1016/j.ijrobp.2017.03.032. doi:10.1016/j.ijrobp.2017.03.032pmid:28721893
[12]	Ilson DH. Advances in the treatment of gastric cancer[J]. Curr Opin Gastroenterol, 2018,34(6):465-468. DOI: 10.1097/MOG.0000000000000475. doi:10.1097/MOG.0000000000000475
[13]	Song JC, Ding XL, Zhang Y, et al. Prospective and prognostic factors for hepatic metastasis of gastric carcinoma: a retrospective analysis[J]. J Cancer Res Ther, 2019,15(2):298-304. DOI: 10.4103/jcrt.JCRT_576_17. doi:10.4103/jcrt.JCRT_576_17pmid:30964101
[14]	Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer[J]. Tumour Biol, 2017,39(7):10104283177-14626. DOI: 10.1177/1010428317714626.
[15]	Ilhan-Mutlu A, Taghizadeh H, Beer A, et al. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: a retrospective single center analysis[J]. Cancer Biol Ther, 2018,19(3):169-174. DOI: 10.1080/15384047.2017.1414759. doi:10.1080/15384047.2017.1414759pmid:29252101
[16]	Wang K, Zhang X, Wei J, et al. Hepatic arterial infusion oxaliplatin plus oral S-1 chemotherapy in gastric cancer with unresectable liver metastases: a case series and literature review[J]. Cancer Manag Res, 2020,12:863-870. DOI: 10.2147/CMAR.S233123. doi:10.2147/CMAR.S233123pmid:32104068
[17]	Ceniceros L, Chopitea A, Pardo F, et al. Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience[J]. Clin Transl Oncol, 2018,20(5):658-665. DOI: 10.1007/s12094-017-1767-2. doi:10.1007/s12094-017-1767-2pmid:29043568
[18]	Ge S, Xia X, Ding C, et al. A proteomic landscape of diffuse-type gastric cancer[J]. Nat Commun, 2018,9(1):1012. DOI: 10.1038/s41467-018-03121-2. doi:10.1038/s41467-018-03121-2
[19]	Lane WO, Nussbaum DP, Sun Z, et al. Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: should lymph node retrieval guidelines be altered[J]. J Surg Oncol, 2018,117(8):1708-1715. DOI: 10.1002/jso.25068. doi:10.1002/jso.25068pmid:29799615
[20]	Guner A, Son T, Cho I, et al. Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation[J]. Gastric Cancer, 2016,19(3):951-960. DOI: 10.1007/s10120-015-0522-z. doi:10.1007/s10120-015-0522-zpmid:26231353
[21]	杨希夷. 高强度聚焦超声联合动脉灌注化疗治疗胃癌术后肝转移的临床疗效评估[J]. 国际肿瘤学杂志, 2015,42(12):950-951. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.018. doi:10.3760/cma.j.issn.1673-422X.2015.12.018
[22]	Liang F. The KEYNOTE-061 trial[J]. Lancet, 2019,393(10176):1098. DOI: 10.1016/S0140-6736(18)33073-3. doi:10.1016/S0140-6736(18)33073-3pmid:30894265
[23]	Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. doi:10.1016/S0140-6736(17)31827-5pmid:28993052
[24]	Gong W, Su Y, Liu A, et al. Clinical characteristics and treatments of patients with alpha-fetoprotein producing gastric carcinoma[J]. Neoplasma, 2018,65(3):326-330. DOI: 10.4149/neo_2018_170207N84. doi:10.4149/neo_2018_170207N84pmid:29788728
[25]	Izuishi K, Mori H. Recent strategies for treating stage Ⅳ gastric cancer: roles of palliative gastrectomy, chemotherapy, and radiothe-rapy[J]. J Gastrointestin Liver Dis, 2016,25(1):87-94. DOI: 10.15403/jgld.2014.1121.251.rv2. doi:10.15403/jgld.2014.1121.251.rv2pmid:27014758
[26]	Omori H, Tanizawa Y, Makuuchi R, et al. Role of palliative resection in patients with incurable advanced gastric cancer who are unfit for chemotherapy[J]. World J Surg, 2019,43(2):571-579. DOI: 10.1007/s00268-018-4816-2. doi:10.1007/s00268-018-4816-2pmid:30298282
[27]	Tokunaga M, Makuuchi R, Miki Y, et al. Surgical and survival outcome following truly palliative gastrectomy in patients with incurable gastric cancer[J]. World J Surg, 2016,40(5):1172-1177. DOI: 10.1007/s00268-015-3398-5. doi:10.1007/s00268-015-3398-5pmid:26754075

Advance in comprehensive treatment of liver metastasis of gastric cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献27

相关文章15

编辑推荐

Metrics

本文评价

[1]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	解淑萍, 孙亚红, 汪超.早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[5]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[6]	邵慧芳, 王学红, 芦永福.CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[7]	朱思雨, 王学红, 李文茜, 刘曙.胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[8]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平.GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[9]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳.沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[10]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文.血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[11]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻.胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[12]	杨俊, 李荣, 曾建昌.复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[13]	邓莉莉, 段星宇, 李保中.HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[14]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦.伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.
[15]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩.人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.